Literature DB >> 9652757

Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes.

S C Clifford1, K Czapla, F M Richards, D J O'Donoghue, E R Maher.   

Abstract

Hepatocyte growth factor (HGF/SF) is a potent renal proximal tubular cell (PTEC) mitogen involved in renal development. HGF/SF is the functional ligand for the c-met proto-oncogene, and germline c-met mutations are associated with familial papillary renal cell carcinoma. Somatic von Hippel-Lindau disease tumour-suppressor gene (VHL) mutations are frequently detected in sporadic clear cell renal cell carcinomas (RCC), and germline VHL mutations are the commonest cause of familial clear cell RCC. pVHL binds to the positive regulatory components of the trimeric elongin (SIII) complex (elongins B and C) and has been observed to deregulate expression of the vascular endothelial growth factor (VEGF) gene. HGF/SF has similarly been reported to up-regulate expression of the VEGF gene in non-renal experimental systems. To investigate the mechanism of HGF/SF action in PTECs and, specifically, to examine potential interactions between the HGF/c-met and the VHL-mediated pathways for renal tubular growth control, we have isolated untransformed PTECs from normal kidneys, developed conditions for their culture in vitro and used these cells to investigate changes in mRNA levels of the VHL, elongin A, B and C, VEGF, c-myc, c-fos and c-met genes after HGF/SF exposure. Significant elevations in the mRNA levels of VEGF, c-myc, c-fos, c-met and elongins A, B and C, but not VHL, were detected after HGF/SF stimulation of human PTECs (P < 0.02), with a consistent order of peak levels observed over successive replicates (c-fos at 1 h, VEGF at 2-4 h, c-myc, at 4 h, followed by c-met and all three elongin subunits at 8 h). This study highlights the spectrum of changes in gene expression observed in PTECs after HGF/SF stimulation and has identified possible candidate mediators of the HGF/SF-induced mitogenic response. Our evidence would suggest that the changes in PTEC VEGF expression induced by HGF/SF are mediated by a VHL-independent pathway.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9652757      PMCID: PMC2150185          DOI: 10.1038/bjc.1998.235

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  47 in total

Review 1.  Control of c-myc regulation in normal and neoplastic cells.

Authors:  C A Spencer; M Groudine
Journal:  Adv Cancer Res       Date:  1991       Impact factor: 6.242

2.  Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction.

Authors:  T Horikoshi; K D Danenberg; T H Stadlbauer; M Volkenandt; L C Shea; K Aigner; B Gustavsson; L Leichman; R Frösing; M Ray
Journal:  Cancer Res       Date:  1992-01-01       Impact factor: 12.701

3.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

Authors:  L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

4.  Vascular permeability factor, an endothelial cell mitogen related to PDGF.

Authors:  P J Keck; S D Hauser; G Krivi; K Sanzo; T Warren; J Feder; D T Connolly
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

5.  Clinical features and natural history of von Hippel-Lindau disease.

Authors:  E R Maher; J R Yates; R Harries; C Benjamin; R Harris; A T Moore; M A Ferguson-Smith
Journal:  Q J Med       Date:  1990-11

Review 6.  The vascular endothelial growth factor family of polypeptides.

Authors:  N Ferrara; K A Houck; L B Jakeman; J Winer; D W Leung
Journal:  J Cell Biochem       Date:  1991-11       Impact factor: 4.429

7.  Hepatocyte growth factor stimulates phosphoinositide hydrolysis and mitogenesis in cultured renal epithelial cells.

Authors:  R C Harris; K D Burns; M Alattar; T Homma; T Nakamura
Journal:  Life Sci       Date:  1993       Impact factor: 5.037

8.  The block to transcriptional elongation within the human c-myc gene is determined in the promoter-proximal region.

Authors:  A Krumm; T Meulia; M Brunvand; M Groudine
Journal:  Genes Dev       Date:  1992-11       Impact factor: 11.361

9.  Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumor.

Authors:  G R Dressler; E C Douglass
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

10.  Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation.

Authors:  G Breier; U Albrecht; S Sterrer; W Risau
Journal:  Development       Date:  1992-02       Impact factor: 6.868

View more
  3 in total

1.  Effect of c-fos antisense probe on prostaglandin E2-induced upregulation of vascular endothelial growth factor mRNA in human liver cancer cells.

Authors:  Yong-Qi Li; Kai-Shan Tao; Ning Ren; Yi-Hu Wang
Journal:  World J Gastroenterol       Date:  2005-07-28       Impact factor: 5.742

2.  Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter.

Authors:  M Zatyka; C Morrissey; I Kuzmin; M I Lerman; F Latif; F M Richards; E R Maher
Journal:  J Med Genet       Date:  2002-07       Impact factor: 6.318

3.  Impact of ischemia and procurement conditions on gene expression in renal cell carcinoma.

Authors:  Nick W Liu; Thomas Sanford; Ramaprasad Srinivasan; Jack L Liu; Kiranpreet Khurana; Olga Aprelikova; Vladimir Valero; Charles Bechert; Robert Worrell; Peter A Pinto; Youfeng Yang; Maria Merino; W Marston Linehan; Gennady Bratslavsky
Journal:  Clin Cancer Res       Date:  2012-11-07       Impact factor: 12.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.